{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:31:53Z","timestamp":1787697113874,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The burden of Parkinson\u2019s disease (PD) worsens with disease progression. However, the lack of objective and uniform disease classification challenges our understanding of the incremental burden in patients with advanced Parkinson\u2019s disease (APD) and suboptimal medication control. The 5\u20132-1 criteria was proposed by clinical consensus to identify patients with advancing PD. Our objective was to evaluate the screening accuracy and incremental clinical burden, healthcare resource utilization (HCRU), and humanistic burden in PD patients meeting the 5\u20132-1 screening criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were drawn from the Adelphi Parkinson\u2019s Disease Specific Program (DSP\u2122), a multi-country point-in-time survey (2017\u20132020). People with PD who were naive to device-aided therapy and on oral PD therapy were included. Patients meeting the 5\u20132-1 screening criteria had one or more of the three clinical indicators of APD: (i) \u22655 doses of oral levodopa\/day, OR (ii) \u201coff\u201d symptoms for \u22652\u2009h of waking day, OR (iii) \u22651\u2009h of troublesome dyskinesia. Clinician assessment of PD stage was used as the reference in this study. Clinical screening accuracy of the 5\u20132-1 criteria was assessed using area under the curve and multivariable logistic regression models. Incremental clinical, HCRU, and humanistic burden were assessed by known-group comparisons between 5 and 2-1-positive and negative patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From the analytic sample (<jats:italic>n<\/jats:italic>\u00a0=\u20094714), 33% of patients met the 5\u20132-1 screening criteria. Among physician-classified APD patients, 78.6% were 5\u20132-1 positive. Concordance between clinician judgment and 5\u20132-1 screening criteria was &gt;\u200975%. 5\u20132-1-positive patients were nearly 7-times more likely to be classified as APD by physician judgment. Compared with the 5\u20132-1-negative group, 5\u20132-1-positive patients had significantly higher clinical, HCRU, and humanistic burden across all measures. In particular, 5\u20132-1-positive patients had 3.8-times more falls, 3.6-times higher annual hospitalization rate, and 3.4-times greater dissatisfaction with PD treatment. 5\u20132-1-positive patients also had significantly lower quality of life and worse caregiver burden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>5\u20132-1 criteria demonstrated potential as a screening tool for identifying people with APD with considerable clinical, humanistic, and HCRU burden. The 5\u20132-1 screening criteria is an objective and reliable tool that may aid the timely identification and treatment optimization of patients inadequately controlled on oral PD medications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02560-1","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T09:04:18Z","timestamp":1643015058000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Does the 5\u20132-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5\u20132-1-positive patients in 7 countries"],"prefix":"10.1186","volume":"22","author":[{"given":"Irene A.","family":"Malaty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Martinez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Skorvanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohi","family":"Jimenez-Shahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Soileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Lindvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefa","family":"Domingos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alobaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash J.","family":"Jalundhwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna L.","family":"Kandukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Onuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Femia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"issue":"s1","key":"2560_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3\u20138.","journal-title":"J Parkinsons Dis"},{"issue":"11","key":"2560_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"GBD 2015 Neurological Disorders Collaborator Group","year":"2017","unstructured":"GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877\u201397.","journal-title":"Lancet Neurol"},{"key":"2560_CR3","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.prdoa.2020.100046","volume":"3","author":"N Dahodwala","year":"2020","unstructured":"Dahodwala N, Pettit AR, Jahnke J, Li P, Ladage VP, Kandukuri PL, et al. Use of a medication-based algorithm to identify advanced Parkinson's disease in administrative claims data: associations with claims-based indicators of disease severity. Clin Parkinsonism Relat Disord. 2020;3:100046.","journal-title":"Clin Parkinsonism Relat Disord"},{"issue":"12","key":"2560_CR4","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063\u201373.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2560_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/mds.25708","volume":"29","author":"S Marrinan","year":"2014","unstructured":"Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson's disease. Mov Disord. 2014;29(1):23\u201332.","journal-title":"Mov Disord"},{"issue":"9","key":"2560_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.nrl.2013.05.002","volume":"28","author":"J Kulisevsky","year":"2013","unstructured":"Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, et al. Advanced Parkinson's disease: clinical characteristics and treatment. Part II. Neurologia. 2013;28(9):558\u201383.","journal-title":"Neurologia"},{"issue":"5","key":"2560_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/ane.12733","volume":"136","author":"E Dietrichs","year":"2017","unstructured":"Dietrichs E, Odin P. Algorithms for the treatment of motor problems in Parkinson's disease. Acta Neurol Scand. 2017;136(5):378\u201385.","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"2560_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.parkreldis.2015.07.020","volume":"21","author":"P Odin","year":"2015","unstructured":"Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21(10):1133\u201344.","journal-title":"Parkinsonism Relat Disord"},{"key":"2560_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fnagi.2016.00121","volume":"8","author":"S Lerche","year":"2016","unstructured":"Lerche S, Heinzel S, Alves GW, Barone P, Behnke S, Ben-Shlomo Y, et al. Aiming for study comparability in Parkinson's disease: proposal for a modular set of biomarker assessments to be used in longitudinal studies. Front Aging Neurosci. 2016;8:121.","journal-title":"Front Aging Neurosci"},{"issue":"12","key":"2560_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00702-017-1799-3","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova N, Martinez-Martin P, Katunina E, Chaudhuri K. Advanced Parkinson's or \"complex phase\" Parkinson's disease? Re-evaluation is needed. J Neural Transm (Vienna). 2017;124(12):1529\u201337.","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"2560_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342.","journal-title":"Neurology."},{"issue":"10","key":"2560_CR12","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/ene.13976","volume":"26","author":"P Martinez-Martin","year":"2019","unstructured":"Martinez-Martin P, Radicati FG, Rodriguez Blazquez C, Wetmore J, Kovacs N, Ray Chaudhuri K, et al. Extensive validation study of the Parkinson's disease composite scale. Eur J Neurol. 2019;26(10):1281\u20138.","journal-title":"Eur J Neurol"},{"key":"2560_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41531-018-0056-2","volume":"4","author":"P Martinez-Martin","year":"2018","unstructured":"Martinez-Martin P, Kulisevsky J, Mir P, Tolosa E, Garc\u00eda-Delgado P, Luquin MR. Validation of a simple screening tool for early diagnosis of advanced Parkinson's disease in daily practice: the CDEPA questionnaire. NPJ Parkinsons Dis. 2018;4:20.","journal-title":"NPJ Parkinsons Dis"},{"issue":"9","key":"2560_CR14","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020\u20138.","journal-title":"Mov Disord"},{"key":"2560_CR15","first-page":"4047392","volume":"2017","author":"MR Luquin","year":"2017","unstructured":"Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the definition of advanced Parkinson's disease: a neurologists-based Delphi study (CEPA study). Parkinsons Dis. 2017;2017:4047392.","journal-title":"Parkinsons Dis"},{"key":"2560_CR16","first-page":"7537924","volume":"2020","author":"D Santos-Garc\u00eda","year":"2020","unstructured":"Santos-Garc\u00eda D, de Deus FT, Su\u00e1rez Castro E, Aneiros D\u00edaz A, McAfee D. 5\u20132-1 Criteria: A Simple Screening Tool for Identifying Advanced PD Patients Who Need an Optimization of Parkinson's Treatment. Parkinsons Dis. 2020;2020:7537924.","journal-title":"Parkinsons Dis"},{"issue":"1","key":"2560_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","volume":"19","author":"A Fasano","year":"2019","unstructured":"Fasano A, Fung VSC, Lopiano L, Elibol B, Smolentseva IG, Seppi K, et al. Characterizing advanced Parkinson's disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019;19(1):50.","journal-title":"BMC Neurol"},{"key":"2560_CR18","doi-asserted-by":"crossref","unstructured":"Moes HR, ten Kate J, Portman AT, van Harten B, van Kesteren ME, Mondria T, et al. Timely referral for advanced therapy in Parkinson\u2019s disease. Development of a screening tool. medRxiv. 2021:2021.02.10.21251496. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.02.10.21251496v1.","DOI":"10.1101\/2021.02.10.21251496"},{"issue":"5","key":"2560_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2217\/nmt-2020-0021","volume":"10","author":"J Aldred","year":"2020","unstructured":"Aldred J, Anca-Herschkovitsch M, Antonini A, Bajenaru O, Bergmann L, Bourgeois P, et al. Application of the \u20185-2-1\u2019 screening criteria in advanced Parkinson\u2019s disease: interim analysis of DUOGLOBE. Neurodegener Dis Manag. 2020;10(5):309\u201323.","journal-title":"Neurodegener Dis Manag"},{"issue":"11","key":"2560_CR20","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific Programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"2560_CR21","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease","year":"2003","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The unified Parkinson's disease rating scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738\u201350.","journal-title":"Mov Disord"},{"issue":"9","key":"2560_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1532-5415.1992.tb01992.x","volume":"40","author":"TN Tombaugh","year":"1992","unstructured":"Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40(9):922\u201335.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"2560_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"3","key":"2560_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 1995;4(3):241\u20138.","journal-title":"Qual Life Res"},{"issue":"2","key":"2560_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","volume":"15","author":"NJ Devlin","year":"2017","unstructured":"Devlin NJ, Brooks R. EQ-5D and the EuroQol group: past, present and future. Appl Health Econ Health Policy. 2017;15(2):127\u201337.","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"2560_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/geront\/20.6.649","volume":"20","author":"SH Zarit","year":"1980","unstructured":"Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20(6):649\u201355.","journal-title":"Gerontologist."},{"issue":"7","key":"2560_CR27","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00134-003-1761-8","volume":"29","author":"JE Fischer","year":"2003","unstructured":"Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29(7):1043\u201351.","journal-title":"Intensive Care Med"},{"issue":"1\u20132","key":"2560_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0167-5877(00)00115-X","volume":"45","author":"M Greiner","year":"2000","unstructured":"Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med. 2000;45(1\u20132):23\u201341.","journal-title":"Prev Vet Med"},{"issue":"4857","key":"2560_CR29","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1126\/science.3287615","volume":"240","author":"JA Swets","year":"1988","unstructured":"Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285\u201393.","journal-title":"Science."},{"issue":"4","key":"2560_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00415-010-5793-z","volume":"258","author":"A Antonini","year":"2011","unstructured":"Antonini A, Isaias IU, Rodolfi G, Landi A, Natuzzi F, Siri C, et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol. 2011;258(4):579\u201385.","journal-title":"J Neurol"},{"issue":"9","key":"2560_CR31","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jocn.2012.10.030","volume":"20","author":"T Simuni","year":"2013","unstructured":"Simuni T, Luo ST, Chou KL, Fernandez H, He B, Parashos S. Rankin scale as a potential measure of global disability in early Parkinson's disease. J Clin Neurosci. 2013;20(9):1200\u20133.","journal-title":"J Clin Neurosci"},{"issue":"1","key":"2560_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.11138\/FNeur\/2017.32.1.028","volume":"32","author":"M Pistacchi","year":"2017","unstructured":"Pistacchi M, Gioulis M, Sanson F, De Giovannini E, Filippi G, Rossetto F, et al. Gait analysis and clinical correlations in early Parkinson's disease. Funct Neurol. 2017;32(1):28\u201334.","journal-title":"Funct Neurol"},{"issue":"11","key":"2560_CR33","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/mds.23135","volume":"25","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Molloy S. P GB, Chaudhuri KR, Piccini P. Parkinson's disease symptoms: the patient's perspective. Mov Disord. 2010;25(11):1646\u201351.","journal-title":"Mov Disord"},{"key":"2560_CR34","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/JMDH.S27180","volume":"4","author":"J L\u00f6kk","year":"2011","unstructured":"L\u00f6kk J. Lack of information and access to advanced treatment for Parkinson's disease patients. J Multidiscip Healthc. 2011;4:433\u20139.","journal-title":"J Multidiscip Healthc"},{"issue":"1","key":"2560_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2047-9158-4-1","volume":"4","author":"H Chen","year":"2015","unstructured":"Chen H, Zhao EJ, Zhang W, Lu Y, Liu R, Huang X, et al. Meta-analyses on prevalence of selected Parkinson's nonmotor symptoms before and after diagnosis. Transl Neurodegener. 2015;4(1):1.","journal-title":"Transl Neurodegener"},{"issue":"7","key":"2560_CR36","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3109\/00207454.2012.657381","volume":"122","author":"RA Hauser","year":"2012","unstructured":"Hauser RA, Lyons KE, Pahwa R. The UPDRS-8: a brief clinical assessment scale for Parkinson's disease. Int J Neurosci. 2012;122(7):333\u20137.","journal-title":"Int J Neurosci"},{"key":"2560_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/bs.irn.2017.03.003","volume":"132","author":"N Titova","year":"2017","unstructured":"Titova N, Qamar MA, Chaudhuri KR. Biomarkers of Parkinson's disease: an introduction. Int Rev Neurobiol. 2017;132:183\u201396.","journal-title":"Int Rev Neurobiol"},{"issue":"6","key":"2560_CR38","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/mds.27302","volume":"33","author":"S Weir","year":"2018","unstructured":"Weir S, Samnaliev M, Kuo TC, Tierney TS, Walleser Autiero S, Taylor RS, et al. Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK. Mov Disord. 2018;33(6):974\u201381.","journal-title":"Mov Disord"},{"key":"2560_CR39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.parkreldis.2021.10.009","volume":"92","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Schmidt P, Cubillos F, Standaert DG, Henriksen T, et al. Validation and clinical value of the MANAGE-PD tool: a clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications. Parkinsonism Relat Disord. 2021;92:59\u201366.","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"2560_CR40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435\u201350.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"2560_CR41","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/WCO.0000000000000112","volume":"27","author":"JG Goldman","year":"2014","unstructured":"Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson's disease. Curr Opin Neurol. 2014;27(4):434\u201341.","journal-title":"Curr Opin Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02560-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02560-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02560-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T09:07:14Z","timestamp":1643015234000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02560-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2560"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02560-1","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Disease Specific Programme was conducted in accordance with the European Pharmaceutical Market Research Association (EphMRA) Code of Conduct. The study protocol (reference number AG8689) was submitted to the Western Institutional Review Board, and an ethics waiver was provided as it was determined that ethics approval was not required for this study. All data were collected following procedures with ethics committee approval, and data were fully de identified prior to receipt by Adelphi Real World. The respondents provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. All data, i.e. methodology, materials, data, and data analysis, that support the findings of this survey are the intellectual property of Adelphi Real World. As such no administrative permissions were required to access and use the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IAM has participated in research funded by Parkinson Foundation, Tourette Association of America, Dystonia Coalition, AbbVie, Biogen, Boston Scientific, Eli Lilly, Impax, Neuroderm, Prilenia, Revance, and Teva but has no owner interest in any pharmaceutical company. She has received travel compensation or honoraria from Cleveland Clinic, Parkinson Foundation, Tourette Association, and International Association of Parkinsonism and Related Disorders and royalties from Robert Rose Publishers; PMM has received honoraria from Editorial Viguera and Takeda Pharmaceuticals for lecturing in courses; from Britannia for writing an article in their Parkinson\u2019s Disease Medical Journal-Kinetic; and from the International Parkinson and Movement Disorder Society (MDS) for management of the Program on Rating Scales. Grants from the MDS for development and validation of the MDS-NMS; SAJ has no relevant disclosures; KRC has received educational funding from UCB, and honoraria for sponsored symposiums from UCB, AbbVie, Britannia, US Worldmeds, Otsuka, Medtronic, Zambon and acted as a consultant for AbbVie, UCB, Britannia, Medtronic and Mundipharama; JJ-S has received consulting fees from Teva, Nuvelution, Bracket, Amneal, Revance, AbbVie, CNS Ratings, St. Jude Medical, Medtronic and research funding from Impax; PO has received compensations for consultancy and speaker related activities from AbbVie, Bial, Britannia, Ever Pharma, Lobsor, Nordic Infucare, Stada, and Zambon. Odin has received royalties from Uni-Med Verlag; MS received speakers\u2019 honoraria and\/or consultation fees from AbbVie, Boston Scientific, Desitin, Ever Pharma, Krka, Medtronic and Sandoz, he received support from the IBM and Slovak grant agencies under contracts APVV-18-0547 and VEGA 1\/0596\/19 and the Operational Programme Integrated Infrastructure, funded by the ERDF under No. ITMS2014+:313011\u2009V455; MJS has received honoraria and\/or consultation fees from AbbVie, Abbott, Acorda Therapeutics, Amneal, Teva, Sunovion, Neurocrine, Medtronic, and Merz. He has also received research compensation from Cerevel and AbbVie; SL declares no relevant conflict of interest to present study; JD declares no relevant conflict of interest to present study; AlA, YJJ, PLK, KO, LB, SF, and MYL are employees of AbbVie and may own stocks\/shares in the company; JW is an employee of Adelphi Real World, a consulting company that was hired by AbbVie to perform analyses on the Adelphi Disease Specific Programme database; AnA has received compensation for consultancy and speaker related activities from UCB, Boehringer Ingelheim, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Neuroderm, Theravance Biopharma, Roche; he receives research support from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 - Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation. He serves as consultant for Boehringer Ingelheim for legal cases on pathological gambling.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}